Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : APL-1030
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Apellis Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : APL-1030, a potential first-in-class, brain-active C3 inhibitor for neurodegenerative and other complement-driven diseases, and APL-2006, an ophthalmological candidate in development to treat both wet age-related macular degeneration (AMD) and geographic...
Product Name : APL-1030
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 22, 2022
Lead Product(s) : APL-1030
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Apellis Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
